80results about How to "Rapid reconstitution" patented technology

The present invention relates to a method of using a superfine pulverizing technology to prepare sterile powder for injection (powder injection) of chemical medicine and the prepared medicine powder injection. Invert sugar, clindamycin phosphate, cefpiramide sodium, cefepime hydrochloride, latamoxef sodium or cefmetazole sodium are preferable as the chemical medicine.

The present invention discloses an active collagen lyophilized powder and a preparation method thereof. A rat tail collagen, polyols, mycose and citric acid are compounded, so that the stability of the rat tail collagen in a freeze-drying process may be jointly improved, a prepared lyophilized product may be stored without a preservative for a long time and is good in redissolution property, capable of keeping the natural bioactivity of collagen and remarkable in capability of promoting the synthesis of collagen in the skin.

The invention belongs to the field of medicine and provides a bortezomib freeze-dried composition and a preparation method thereof. The bortezomib freeze-dried composition is a freeze-dried composition which is obtained through the steps of spraying the mixed solution of bortezomib, mannitol and tertiary butanol into liquid nitrogen to form frozen microparticles, dissolving the microparticles in water for injection, and finally, performing freeze-drying. The bortezomib freeze-dried composition provided by the invention is better in quality and higher in stability.

The invention discloses an asparaginase freeze-dried powder injection. The injection comprises asparaginase, a buffering agent, a surfactant, medical auxiliary materials and 5% of injection water which is used as a solvent in a preparing process and less than the addition finally, wherein the surfactant is a nonionic surfactant; and the buffering agent and the nonionic surfactant are added into the formula, so that the situation that tiny visible particles exceed standard is prevented when the asparaginase is dissolved and transferred into an injection. The invention also discloses a dedicated solution for dissolving the asparaginase, wherein the solution solvent is the injection water, and the solute comprises the buffering agent and the surfactant. On the premise of not changing the conventional formula of the freeze-dried powder injection, when the freeze-dried powder is dissolved in the solution, and is transferred into sodium chloride or a glucose injection, the situation that tiny visible particles exceed standard is prevented, so that the stimulation to human bodies is reduced in use, and the clinical administration safety is improved.

The invention relates to a spectinomycin hydrochloride and lincomycin hydrochloride freeze-dried powder injection and a preparation method of the spectinomycin hydrochloride and lincomycin hydrochloride freeze-dried powder injection, and solves the problems of high cost of industrial production and low drug stability in the prior art. The preparation method comprises the steps of firstly preparing a freeze-dried propping agent and antioxidant mixed solution, then preparing a to-be-freeze-dried sample of spectinomycin hydrochloride and lincomycin hydrochloride, and finally preparing the white loose block or powder spectinomycin hydrochloride and lincomycin hydrochloride freeze-dried powder injection in a freeze drying box. According to the spectinomycin hydrochloride and lincomycin hydrochloride freeze-dried powder injection and the preparation method of the spectinomycin hydrochloride and lincomycin hydrochloride freeze-dried powder injection, the drug stability and the bioavailability are high, and the industrial production is realized.

The invention discloses an asparaginase freeze-dried powder injection. The injection comprises asparaginase, a buffering agent, a surfactant, medical auxiliary materials and 5% of injection water which is used as a solvent in a preparing process and less than the addition finally, wherein the surfactant is a nonionic surfactant; and the buffering agent and the nonionic surfactant are added into the formula, so that the situation that tiny visible particles exceed standard is prevented when the asparaginase is dissolved and transferred into an injection. The invention also discloses a dedicated solution for dissolving the asparaginase, wherein the solution solvent is the injection water, and the solute comprises the buffering agent and the surfactant. On the premise of not changing the conventional formula of the freeze-dried powder injection, when the freeze-dried powder is dissolved in the solution, and is transferred into sodium chloride or a glucose injection, the situation that tiny visible particles exceed standard is prevented, so that the stimulation to human bodies is reduced in use, and the clinical administration safety is improved.

The invention belongs to the technical field of medicinal preparations, and relates to an excipient-free lyophilized paclitaxel powder preparation and a preparation method thereof. The lyophilized paclitaxel powder does not contain excipients, adopts paclitaxel as a medicinal effective component, and adopts mPEG- PLA-lysine as a matrix. The preparation method is simple; the excipient-free lyophilized paclitaxel powder preparation adopts mPEG-PLA-lysine with low cytotoxicityas as a carrier, and other auxiliary components are not needed, so the preparation has simple formula and high safety; the excipient-free lyophilized paclitaxel powder preparation has good solubility in water, can be rapidly re-dissolved in water, and has a highest concentration reaching 10mg / ml; and the re-dissolved lyophilized paclitaxel powder preparation has small average particle size, and easily performs an ERP effect.

The invention belongs to the technical field of medicinal preparations, and relates to an excipient-containing lyophilized paclitaxel powder preparation and a preparation method thereof. The preparation adopts paclitaxel as a medicinal effective component, adopts mPEG-PLA-aspartic acid as a matrix, and contains an excipient; and the excipient comprises one or more of lactose, mannitol, dextran, glycine and glucose. The preparation method comprises the following steps: 1, mixing mPEG-PLA-aspartic acid with paclitaxel; 2, fully dissolving the above obtained mixture in an organic solvent; 3, removing the organic solvent; 4, adding water, and hydrating to form a micelle solution; and 5, adding the excipient accounting for 5% or less of the total weight of materials added in step 1 to the medicine-loaded micelle solution, fully dissolving the excipient, lyophilizing the above obtained mixed micelle solution through a routine lyophilizing technology to prepare the excipient-containing lyophilized paclitaxel powder preparation. The excipient-containing lyophilized paclitaxel powder preparation has the advantages of simple preparation method, simple formula, high safety, good dissolution, rapid re-dissolving in water, and realization of small average particle size and easy performance of the ERP effect after the re-dissolving.